Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels
- 1 July 1992
- journal article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 34 (4) , 221-227
- https://doi.org/10.1007/bf01741789
Abstract
Assessment of the tissue distribution of adoptively transferred adherent lymphokine-activated killer A-LAK) cells by use of51Cr indicated that these effector cells, after an initial phase in the lungs, distributed in high numbers to liver and spleen (30% and 10% of injected dose, respectively). However, when this experiment was repeated with125IdUrd as cell label, fewer than 2% and 0.5% of the injected cells distributed into liver and spleen respectively. To analyse this discrepancy, we compared the tissue distribution of51Cr- and125IdUrd-labelled A-LAK cells with that indicated by alternative direct visual methods for identification of the injected cells, such as fluorescent dyes (rhodamine and H33342) or immunohistochemical staining of asialo-GM1-positive cells. The number of i. v. injected A-LAK cells found in the liver by all visual methods ranged from 1% to 5% of the injected dose, supporting the data obtained with125IdUrd, whereas 25%–30% of the51Cr label was consistently found in this organ. Autoradiography of the liver 24 h after i. v. injection of51Cr-labelled cells revealed a background activity that was four- to fivefold higher than the control level, indicating substantial non-specific accumulation in the liver of51Cr released from A-LAK cells. We conclude that51Cr cannot be reliably used in investigations of cell traffic to the liver because of non-specific accumulation of the51Cr label, particularly in this organ. In contrast, labelling with125IdUrd or rhodamine and immunohistochemical staining of asialo-GM1-positive cells appear to be reliable and essentially equivalent methods for investigations of the fate of adoptively transferred A-LAK cells. Using these methods, we found that only few A-LAK cells redistribute to the liver upon i. v., i. e. systemic, injection, whereas 40%–50% of locally (intraportally) injected A-LAK cells remain in the liver for at least 24 h.Keywords
This publication has 30 references indexed in Scilit:
- Comparison between 125IUdR and 51Cr as cell labels in investigations of tumor cell migrationInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1990
- Fate of intravenously administered rat lymphokine-activated killer cells labeled with different markersCancer Immunology, Immunotherapy, 1990
- Lymphocytes Stimulated With Recombinant Human Interleukin-2: Relationship Between Motility Into Protein Matrix and In Vivo Localization in Normal and Neoplastic Tissues of MiceJNCI Journal of the National Cancer Institute, 1990
- Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells.The Journal of Experimental Medicine, 1988
- DNA damage, cytotoxic effect and cell‐cycle perturbation of Hoechst 33342 on L1210 cells in vitroCytometry, 1988
- Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleenImmunology Today, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated LymphocytesAnnual Review of Immunology, 1986
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.The Journal of Experimental Medicine, 1984